Cardiovascular disease on a global scale: defining the path forward for research and practice

被引:29
|
作者
Mark, Daniel B.
De Werf, Frans J. Van
Simes, R. John
White, Harvey D.
Wallentin, Lars C.
Califf, Robert M.
Armstrong, Paul W.
机构
[1] Duke Univ, Med Ctr, Duke Clin Res Inst, Div Cardiol,Dept Med, Durham, NC 27715 USA
[2] Univ Hosp Gathuisberg, Dept Cardiol, Louvain, Belgium
[3] Clin Trials Ctr, Natl Hlth & Med Res Council, Camperdown, NSW, Australia
[4] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand
[5] Univ Hosp, Uppsala Clin Res Ctr, Uppsala, Sweden
[6] Univ Alberta, Dept Med, Edmonton, AB, Canada
关键词
cardiovascular diseases; epidemiology;
D O I
10.1093/eurheartj/ehm411
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
During the 2006 World Congress of Cardiology meeting in Barcelona, the Virtual Coordinating Centre for Global Collaborative Cardiovascular Research (VIGOUR) group held a symposium examining potential approaches to understanding and controlling the explosive worldwide growth of cardiovascular disease and its attendant morbidity and mortality. Over the last 20 years, the global nature of many problems in health care has become much more evident. In the realm of health, this has meant that countries across the globe have started to experience the same kinds of behavioural shifts (overeating, reduced physical activity and smoking), and with them massive increases in cardiovascular risk factors, observed over the last century particularly in North America and Western Europe. This VIGOUR symposium focused on what actions can be taken now to prepare for this future in which prevention and treatment of cardiovascular disease wilt be a major public health issue in a much larger proportion of the world's countries. The participants focused on four major areas where they saw important opportunities: (i) the development of high quality, contemporaneous data sources that can be used to study and improve the processes, treatments and outcomes of cardiovascular diseases globally; (ii) the feasibility and resource/health economic implications of any proposed potential solutions need to be carefully defined; (iii) models/systems must be identified that can be used to guide effective interventions targeting health problems of large populations at an affordable price; (iv) academic research organizations need to assume a more active rote in the health-care system both through their traditional activities in discovery research and developing evidence-based medicine along with translation of research findings into effective interventions that improve the public health.
引用
收藏
页码:2678 / 2684
页数:7
相关论文
共 50 条
  • [41] Moving From Political Declaration to Action on Reducing the Global Burden of Cardiovascular Diseases A Statement From the Global Cardiovascular Disease Taskforce
    Smith, Sidney C., Jr.
    Chen, Deborah
    Collins, Amy
    Harold, John G.
    Jessup, Mariell
    Josephson, Staffan
    Logstrup, Susanne
    Jur, Cand
    Sacco, Ralph L.
    Vardas, Panos E.
    Wood, David A.
    Zoghbi, William A.
    CIRCULATION, 2013, 128 (23) : 2546 - 2548
  • [42] The Path from Research to Successful Implementation in Clinical Practice: Endovascular Treatment in the Netherlands
    Wiegers, Eveline J.
    Compagne, Kars C.
    Venema, Esmee
    Janssen, Paula M.
    Lingsma, Hester F.
    Roozenbeek, Bob
    Van der Lugt, Aad
    Dippel, Diederik W.
    STROKE, 2019, 50
  • [43] CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease - Application to Clinical and Public Health Practice - Overview
    Pearson, TA
    Mensah, GA
    Hong, YL
    Smith, SC
    CIRCULATION, 2004, 110 (25) : E543 - E544
  • [44] The burden of cardiovascular diseases in Ethiopia from 1990 to 2017: evidence from the Global Burden of Disease Study
    Ali, Solomon
    Misganaw, Awoke
    Worku, Asnake
    Destaw, Zelalem
    Negash, Legesse
    Bekele, Abebe
    Briant, Paul S.
    Johnson, Catherine O.
    Alam, Tahiya
    Odell, Chris
    Roth, Gregory A.
    Naghavi, Mohsen
    Abate, Ebba
    Mirkuzie, Alemnesh H.
    INTERNATIONAL HEALTH, 2021, 13 (04): : 318 - 326
  • [45] Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context
    Ntsekhe, Mpiko
    Baker, Jason V.
    CIRCULATION, 2023, 147 (01) : 83 - 100
  • [46] Restless legs syndrome and cardiovascular disease: a research roadmap
    Gottlieb, Daniel J.
    Somers, Virend K.
    Punjabi, Naresh M.
    Winkelman, John W.
    SLEEP MEDICINE, 2017, 31 : 10 - 17
  • [47] Cardiovascular disease, a major global burden: Epidemiology of stroke and ischemic heart disease in Japan
    Iso, Hiroyasu
    GLOBAL HEALTH & MEDICINE, 2021, 3 (06): : 358 - 364
  • [48] Burden of cardiovascular disease among elderly: based on the Global Burden of Disease Study 2019
    Qu, Chunrun
    Liao, Sheng
    Zhang, Jingdan
    Cao, Hui
    Zhang, Hao
    Zhang, Nan
    Yan, Luzhe
    Cui, Gaoyuan
    Luo, Peng
    Zhang, Qingwei
    Cheng, Quan
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2024, 10 (02) : 143 - 153
  • [49] Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease
    Smith, J. Gustav
    Gerszten, Robert E.
    CIRCULATION, 2017, 135 (17) : 1651 - 1664
  • [50] Cardiovascular disease and asymptomatic childhood cancer survivors: Current clinical practice
    Bottinor, Wendy J.
    Friedman, Debra L.
    Ryan, Thomas D.
    Wang, Li
    Yu, Chang
    Borinstein, Scott C.
    Godown, Justin
    CANCER MEDICINE, 2020, 9 (15): : 5500 - 5508